Context: Erectile dysfunction (ED) following radical prostatectomy is a concern for patients and their partners. Low-intensity extracorporeal shockwave therapy (LI-ESWT) can potentially enhance tissue repair and regeneration. The aim of the current study was to systematically review the literature to assess the role of LI-ESWT in the management of patients with postprostatectomy ED.
Evidence Acquisition: Two authors independently performed a systematic search of the PubMed and Web of Science databases to identify all relevant articles. Non-English reports, case reports, reviews, letters, and editorials were excluded. Risk of bias was assessed according to the GRADE guidelines.
Evidence Synthesis: Nine articles met the inclusion criteria and were included in the qualitative analysis. All the studies included were published between 2015 and 2022 and the majority of them compared phosphodiesterase type 5 inhibitors (PDE5Is) alone versus a combination of LI-ESWT and PDE5Is. Only three studies were randomized controlled trials (RCTs). In general, there is no standardized protocol for LI-ESWT for postprostatectomy ED. In comparisons of LI-ESWT + PDE5Is versus PDE5Is alone, some authors found a statistically significant improvement in erectile function with LI-ESWT + PDE5Is. The starting time for LI-ESWT differed among the studies, ranging from 3 d to 6 mo after surgery. The main limitations of the review are the scarcity of studies, small sample sizes, high risk of bias, and high heterogeneity among studies.
Conclusions: There is currently limited evidence on the use of LI-ESWT either alone or in combination with PDE5Is in penile rehabilitation protocols after prostatectomy. However, small clinical trials with short follow-up show that LI-ESWT could potentially play a role in the management of postprostatectomy ED in the future. Further RCTs with larger sample sizes are needed.
Patient Summary: Despite limited reports in the literature, low-intensity shockwave therapy after removal of the prostate is a promising noninvasive treatment for dealing with erectile dysfunction after surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344341 | PMC |
http://dx.doi.org/10.1016/j.euros.2022.07.003 | DOI Listing |
Saudi Med J
January 2025
From the Physiotherapy Department (R. Alfaifi, Juraybi, Alrashed, Alghidani) Al-Rass General Hospital, Al-Rass; from the Neurosurgery Department (H. Alfaifi), Abha Maternity and Child Hospital, Abha, Kingdom of Saudi Arabia.
Objectives: To investigate the long-term effects of Extracorporeal shockwave therapy (ESWT) and ultrasound (US) in treating the trigger finger. Trigger finger, also known as stenosing tenosynovitis, is a common type of tenosynovitis affecting the flexor sheath of any finger. Extracorporeal shockwave therapy and therapeutic US are conservative treatments that use waves of varied frequency to target damaged regions and improve function.
View Article and Find Full Text PDFJ Sex Med
January 2025
Elexial Research Limited, Boston Medical, Department of Clinical Research, Mexico City 11000, Mexico.
Background: Shockwave therapy is an optional adjuvant treatment for vascular erectile dysfunction (ED). There is variability in treatment protocols and challenges with patients adherence to the weekly protocol, which is the most commonly used.
Aim: This study aimed to evaluate the noninferiority of a monthly shockwave therapy protocol compared to the weekly protocol for treating vascular ED.
J Am Coll Cardiol
January 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: https://twitter.com/DLBHATTMD.
Background: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, most but not all randomized trials have reported that complete revascularization (CR) offers advantages over culprit vessel-only revascularization. In addition, the optimal timing and assessment methods for CR remain undetermined.
Objectives: The purpose of this study was to identify the optimal revascularization strategy in patients with STEMI and multivessel disease, using a network meta-analysis of randomized controlled trials.
Am J Cardiol
January 2025
Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Baim Institute for Clinical Research, Boston, MA, USA. Electronic address:
There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). A previously-described blood biomarker panel to predict cardiovascular (CV) events was evaluated in patients with CTO. From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization.
View Article and Find Full Text PDFEuroIntervention
January 2025
Department of Cardiac-Thoracic-Vascular Sciences, University of Padua, Padua, Italy.
This clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions was developed in association with the European Society of Cardiology Working Group on Cardiovascular Surgery. It aims to define procedural and contemporary technical requirements that may improve the efficacy and safety of percutaneous coronary intervention (PCI), both in the acute phase and at long-term follow-up, in a high-risk cohort of patients on optimal medical therapy when clinical and anatomical high-risk criteria are present that entail unacceptable surgical risks, precluding the feasibility of coronary artery bypass grafting (CABG). This document pertains to patients with surgical contraindication according to the Heart Team, in whom medical therapy has failed (e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!